NDA submission to the FDA marks a pivotal step toward US market entry, with improved EBITDA and strong sales growth outside Germany offsetting local headwinds. Financials show higher gross margins and a strengthened liquidity position, supporting continued execution of strategic priorities.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.